Epidemiology of Infection in AML: A European Haematology Association Survey (EPIAMLINF), a multicenter observational study to better understand infections in acute myeloid leukemia (AML).

Principal Investigator: Livio Pagano

Objectives of the study: 

Primary

To assess the incidence of bacterial, fungal, and viral infections in acute myeloid leukemia (AML).

Secondary

• Evaluate the impact of antimicrobial treatment and prophylaxis
• Determine infection-related mortality

Study design:

The present study is an observational, prospective, multicenter, non-interventional study. Inclusion period: March 1, 2025 – February 28, 2026

Population:

Inclusion Criteria:

• Age ≥18 years
• New diagnosis of AML (only cases diagnosed after 01/01/2025), acute promyelocytic leukemia are included
• Patients not eligible to any kind of chemotherapy but only best supportive care
• AML patients treated with induction treatment, consolidation treatment, or relapsed/refractory (for these latter patients the first diagnosis must not be prior to March 01, 2025)
• All kind of infectious diseases, including parasites.
• Clinically or microbiologically diagnosed infections

Exclusion Criteria:

• Hematological diseases, other than AML
• Patients with an AML diagnosis prior to March 2025 but who relapsed during the period under examination
• Patients relapsed after allo or auto-stem cell transplant (Inclusion of post-transplant patients would create an evaluation bias due to the immunological alterations that the transplant procedure causes).